Skip to main content

Pulmonary Hypertension Screening in Patients With Interstitial Lung Disease for Earlier Detection

Completed · NCT05776225

Conditions: Interstitial Lung Disease, Pulmonary Hypertension

At a glance

Research payments reported, 2025
$2.9M
U.S. investigators named
44
Sites paid
42
Planned or actual enrollment
314

About the trial

Sponsor
United Therapeutics
Tested
Right heart catheterization (RHC) (procedure)
Dates
Started 2023-08-11; completion 2026-04-29
Results posted
Not yet

Study GMS-PH-001 is a multicenter, open-label, non-randomized study to prospectively evaluate screening strategies of pulmonary hypertension (PH) in patients with interstitial lung disease (ILD).

From ClinicalTrials.gov, last updated 2026-05-28. Full record, eligibility and contacts (opens in a new tab)

Industry funding

United Therapeutics Corporation reported $2.9M in research payments for this study in 2025 (607 payments).

Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.

U.S. investigators named on this study

Clinicians the company named as principal investigators in its Open Payments reports.

Sites paid to run it

Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.